SILEXION THERAPEUTICS CORP(NASDAQ:SLXN) stock News

SLXN Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Chartmill - Mentions: PBM ATEC FLR TTEC ...

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.

4 days ago - By: Chartmill - Mentions: PBM ATEC FLR TTEC ...

These stocks are moving in today's session

4 days ago - By: Benzinga - Mentions: AMZN ATEC FLR NSP ...

Crude Oil Down 2%; Amazon Shares Tumble After Q2 Results

4 days ago - By: Benzinga - Mentions: PBM ATEC CALC EQ ...

12 Health Care Stocks Moving In Friday's Intraday Session

4 days ago - By: Chartmill - Mentions: ATEC FLR TTEC CPS ...

The market is filled with gapping stocks in Friday's session.

4 days ago - By: Chartmill - Mentions: ATEC CREG MX TILE ...

These stocks that are showing activity before the opening bell on Friday.

4 days ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

5 days ago - By: Chartmill - Mentions: MSW ALGN RCON TROX ...

Here are the top movers in Thursday's session.

5 days ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

20 days ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

a month ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

2 months ago - By: Yahoo Finance - Mentions: CNC EQIX CRM

Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal Tumors

2 months ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers

3 months ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer

3 months ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

4 months ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

5 months ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

5 months ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

5 months ago - By: PESG Research

PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

5 months ago - By: Silexion Therapeutics Corp

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

5 months ago - By: PESG Research

SILEXION THERAPEUTICS CORP (SLXN) Stock News

SLXN Latest News, Press Relases and Analysis

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.

These stocks are moving in today's session

Crude Oil Down 2%; Amazon Shares Tumble After Q2 Results

12 Health Care Stocks Moving In Friday's Intraday Session

The market is filled with gapping stocks in Friday's session.

These stocks that are showing activity before the opening bell on Friday.

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Here are the top movers in Thursday's session.

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

Silexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal Tumors

Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational